The analytic studies presented here show that the cobas EGFR test is a sensitive, accurate, rapid, and reproducible assay for EGFR mutations that allows clinicians to identify those patients with advanced NSCLC who have a high likelihood of benefiting from treatment with anti-EGFR TKI therapies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.